Professor developing nicotine vaccination

By Stephen Underwood

According to the U.S. Department of Health, an estimated 46 million Americans, or roughly 25 percent of the adult population, is addicted to cigarettes. These addictions lead to an estimated 430,000 deaths each year in the U.S. alone, with more than 70 percent of smokers wanting to quit and only 10 percent succeeding.

However, that may soon change. Peter Burkhard, associate professor of molecular and cell biology at UConn, believes he has the answer in curbing nicotine addiction via vaccination.

Burkhard sees smoking as a serious problem.

“Seven million people are killed by the causes of nicotine addiction each year globally. That’s like wiping out Switzerland, every year,” he said.

Burkhard received a five year, $2.5 million Avant-Garde Medications Development Award in order to develop and test a nicotine vaccination.

Nicotine is recognized today by many medical professionals as extremely addictive, and works by stimulating and raising dopamine and seratonin levels in the brain, two hormones responsible for feeling happy.

The vaccination would act much like a virus that activates the immune system.

“When you smoke, nicotine travels from your lungs to your blood, and finally to your brain, where it acts as a stimulant and produces a good feeling, or a kick,” said Burkhard.

The vaccination would effectively be able to train the immune system to recognize nicotine molecules in the bloodstream, and bind them before they can reach the brain, where the user becomes addicted or gets a “high.”

Burkhard, who has previously worked on other vaccinations for diseases such as malaria, has made the vaccine work the same way a vaccine for diseases works. The vaccine would inject a virus-like particle into the bloodstream that would contain nicotine molecules. Thus, the immune system would be tricked into thinking the particle is a virus and would immediately bind the nicotine molecules by producing antibodies.

“This could work for people who are already addicted. We have reason to think it will create a stronger immune response than the other carriers tested as nicotine vaccines,” Burkhard said.

While the vaccination can’t defend against the side effects of smoking such as heart disease, lung cancer and other complications, it can allow users to quit smoking by stopping the addictive nature nicotine produces.

Students’ opinions of the news were positive.

Andrew Glick, a 5th-semester pre-med student said, “Finding a cure to stop nicotine addiction would benefit our world tremendously for a variety of reasons. But most importantly smokers who quit are more likely to have better circulation and lung function, a decreased risk of stroke and, if early enough, a decreased risk of lung cancer. It would also rein in the excessive costs due to treating conditions due to smoking.”

Matt Voghel, a 5th-semester pharmacy major said, “Anything that can help nicotine users quit early could greatly improve their quality of life later on. If the drug manages to make it through testing it would be a great day for a nation fighting nicotine addiction.”

Currently the vaccination will be undergoing clinical trials. Burkhard has stated his optimism in its success and the enormous impact it would have if proven successful. “It would be huge,” said Burkhard.

Read more here: http://www.dailycampus.com/news/professor-developing-nicotine-vaccination-1.2621680
Copyright 2026 The Daily Campus